Chronic Lymphocytic Leukemia
IACH 2021: CAR-T in clinical practice
Currently, five chimeric antigen receptor T-cell (CAR-T) therapies are approved for the treatment of hematological malignancies including acute lymphoblastic leukemia,…
Date: 30th September 2021
Highlights from iwCLL 2021
The management of chronic lymphocytic leukemia (CLL) has evolved drastically over the last few years, with the introduction of novel…
Date: 27th September 2021
EHA 2021: real-world data on myeloma, lymphoma and CLL
Real-world data gained through scientific studies is essential in the advancement of treatments for all hematological malignancies. Historically, pharmaceutical companies…
Date: 25th August 2021
The CLL Sessions: highlights from EHA and ICML 2021
In this roundtable discussion, chaired by Paolo Ghia, MD, PhD, Università Vita-Salute San Raffaele, Milan, Italy; Susan O’Brien, MD, University…
Date: 27th July 2021
EHA 2021: fixed-duration therapies and sequencing in CLL
Over the last years, the chronic lymphocytic leukemia (CLL) field has seen significant growth in new drugs and new treatment…
Date: 8th July 2021
Latest updates on CAR-T therapy for CLL
Chronic lymphocytic leukemia (CLL) is slow to develop and can be hard to treat as patients relapse or become refractory…
Date: 16th June 2021
The CLL Sessions: highlights from ASH 2020
Chronic lymphocytic leukemia (CLL), also known as B-cell CLL (B-CLL) is the most common leukemia in Europe and North America….
Date: 17th March 2021
Developments in CLL: MRD, LOXO-305 and venetoclax at ASH 2020
Chronic Lymphocytic Leukemia (CLL) is a B-cell malignancy, predominantly affecting the elderly, which is characterized by an accumulation of immunologically…
Date: 28th January 2021
CLL: MRD and first-in class agents
Chronic lymphocytic leukemia (CLL) is a disorder characterized by morphologically mature but immunologically less mature lymphocytes, which accumulate in the…
Date: 13th August 2020
The CLL Sessions: frontline therapy, BTK inhibitors, MRD negativity & novel therapies
A remarkable increase in the understanding of the pathogenesis of chronic lymphocytic leukemia (CLL) has led to the development of…
Date: 31st July 2020
The HemOnc & COVID-19 Sessions: treating hematological malignancies, reducing nosocomial COVID-19 infections, clinical trial participation and resource allocation
The ongoing COVID-19 pandemic caused by SARS-CoV-2 is an international public health issue and patients with cancer consistently demonstrate poorer…
Date: 28th July 2020
CAR-T in the CLL space
Novel combinations work well for many patients suffering from chronic lymphocytic leukemia (CLL), but there is a subset of patients…
Date: 2nd April 2020